Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Autolus Therapeutics (AUTL) Other financing activities (2022 - 2024)

Autolus Therapeutics (AUTL) has disclosed Other financing activities for 3 consecutive years, with $1.8 million as the latest value for Q2 2024.

  • For the quarter ending Q2 2024, Other financing activities rose 740.18% year-over-year to $1.8 million, compared with a TTM value of $1.8 million through Mar 2025, down 93.37%, and an annual FY2024 reading of $29.4 million, up 3126.37% over the prior year.
  • Other financing activities was $1.8 million for Q2 2024 at Autolus Therapeutics, down from $27.5 million in the prior quarter.
  • Across five years, Other financing activities topped out at $27.5 million in Q1 2024 and bottomed at $219000.0 in Q2 2023.
  • Average Other financing activities over 3 years is $8.1 million, with a median of $1.8 million recorded in 2024.
  • Peak annual rise in Other financing activities hit 3882.63% in 2024, while the deepest fall reached 740.18% in 2024.
  • Year by year, Other financing activities stood at $10.3 million in 2022, then crashed by 97.88% to $219000.0 in 2023, then surged by 740.18% to $1.8 million in 2024.
  • Business Quant data shows Other financing activities for AUTL at $1.8 million in Q2 2024, $27.5 million in Q1 2024, and $219000.0 in Q2 2023.